Mark Trusheim is Strategic Director, MIT NEWDIGS where he also co-leads the Financing and reimbursement of Cures in the US (FoCUS) Project; and a Visiting Scientist at the MIT Sloan School of Management. Through MIT he has also served as a Special Government Employee for the FDA’s Office of the Commissioner.
Mark’s research focuses on the economics of biomedical innovation, especially precision financing for patient access, precision medicine, adaptive pathways, platform trials, biosimilars, and digital health advances.
Mark is also President of Co-Bio Consulting, LLC. Prior to MIT, his career spanned big data at Kenan Systems, marketing at Searle Pharmaceuticals, eHealth as Vice President of Monsanto Health Solutions, genomics as President of Cereon Genomics, and policy as the President of the Massachusetts Biotechnology Council.
He holds degrees in Chemistry from Stanford University and Management from MIT.
SPEAKER: ADAPTIVE PATHWAYS: GENERATING EVIDENCE OF VALUE